Thursday, 8 May 2008

CIRM Award Funds to Build California Stem Cell Labs

Next big investment in stem cell research in California Wednesday, 07 May 2008 CIRM, Donors and 12 California Institutions Commit $1.1 Billion to Stem Cell Research in California. The governing board of the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency, voted today to distribute $271 million to 12 institutions to build stem cell research facilities throughout California. The institutions committed an additional $560 million from charitable donations and their internal reserves, bringing the total state-wide investment in new research space to $831 million. This leverage of the state’s stem cell funds was further increased by additional institutional commitments for faculty recruitment packages and other related capital costs. In total, the state funding will have leveraged $1.1 billion in new resources to accelerate the pace toward therapies for patients with chronic and debilitating disease and injury. Investment in research infrastructure to extend California’s state-of-the-art research capacity is a critical part of the agency’s scientific strategic plan to sustain and build California’s global leadership in stem cell research and to accelerate the field as a whole. All the institutions have agreed to expedited construction schedules that will deliver nearly 800,000 square feet of facilities with researchers in the labs within two years. This accelerated schedule should create thousands of construction jobs at a time when the state economy needs them. “This Prop. 71 stem cell research facilities program is one of the largest building programs ever dedicated for a new field of medical science and it will deliver an impact that will be felt world-wide,” commented Robert N. Klein, chairman of the governing board of the state stem cell agency. “As a patient advocate, I am inspired by the amount of leverage California research institutions have contributed from their charitable donors and from their reserves. Their incredible commitment underscores the promise that stem cell research holds for patients suffering from chronic disease and injury.” In a statement issued today, Governor Schwarzenegger said: “This will go a long way toward medical research that could save lives and improve them for people with chronic diseases. But also, this kind of public-private investment in a growing jobs sector is exactly the kind of good news our economy needs right now.” The Major Facilities Grant program was launched in August 2007 as a two-part application process. In the fall, the agency’s Scientific and Medical Research Grants Working Group evaluated the scientific merit of 17 proposals submitted in response to the request for application. On January 16, 2008 the ICOC approved Part 1 of the applications, inviting 12 institutions to advance to the second and final part of the application process. Part 2 of the application focuses on the technical aspects of an applicant’s building program and how the scientific program aligns with the CIRM’s objectives, and why the program represents a good value for California taxpayers’ investment. The review was conducted by the 10-member Scientific and Medical Research Facilities Working Group (Facilities Working Group) made up of real estate experts, patient advocates and the chairman of the ICOC. This meeting was open to the public. “These facilities will house basic and clinical researchers working collaboratively, with stem-cell-specific core labs literally ‘down the hall’ – an arrangement that is instrumental to our ability to accelerate the pace of research toward clinical application” said Dr. Alan Trounson, president of CIRM. “Because of this, we believe these facilities will be an instrumental part of advancing one of CIRM’s primary objectives of helping to speed the delivery of stem-cell based therapies and cures into the clinic and to patients.” CIRM had originally pledged to award $262 million in this round of grants, which would have taken the facilities grants by CIRM to the maximum allowed for “bricks and mortar” under Proposition 71. Today’s total of $271 million results from asking the institutions to breakout costs for scientific equipment, which CIRM routinely funds from the research portion of its bond allocation. This allowed CIRM to supplement its facilities total with $9 million from the research pool. “I was very pleased that the review process allowed us to make complete, thorough and fair evaluations of the applications,” said David Lichtenger, Chair of the CIRM Facilities Working Group (FWG), and President and CEO of Integrated Facilities Solutions (IFS) in Palo Alto. “I was also very encouraged to see that many of the applicants are at the forefront in designing innovative research space that efficiently used open and common areas to foster collaboration and flexibility in use.” “I am thrilled that there appears to be sufficient funds that all 12 proposals can move forward to completion because these facilities should dramatically accelerate the pace of getting new therapies to patients,” said David Serrano Sewell, vice chair of the CIRM FWG and Deputy City Attorney in the San Francisco City Attorney’s Office. The 12 institutions had originally requested $336 million in funding from CIRM. At its April 4 - 5 meeting the FWG scored each proposal on set criteria and then reduced each institution’s request by the percentage their score was below 100. For example, if a proposal received a 92, the institution’s request was reduced by eight percent. That reduced the funding gap from $74 million to $27 million. Moving $9 million of the requests into equipment costs reduced the gap to $18 million. This remaining gap was mitigated by offering institutions the chance to receive their award this summer at a discounted rate, rather than two years from now at completion of the projects as was initially contemplated. Eight institutions decided it was financially advantageous for them to take the award now with a nine percent reduction. This closed the gap and the remaining, relatively new and emerging institutions, could get the full funding recommended by the FWG. “California is at the epicenter of stem cell research,” said Eli Broad, founder of The Eli and Edythe Broad Foundation, which has committed more than $50 million to stem cell research at the Broad Institute for Integrative Biology and Stem Cell Research at USC and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. “By creating new research centers and attracting the very best scientists from around the world, we will enable the rapid progress of one of the most promising areas of scientific and medical research today. The partnership between public institutions, the state, private foundations and donors demonstrates the unprecedented commitment California is making to stem cell research. The Broad Foundation is pleased to be the largest private donor to stem cell research in California.” "The important thing to me is that stem cells might not only extend life, but also improve the quality of life, as so many people suffer in their later years. But I think stem cells will have applications across the entire life span" stated Lorry Lokey, a donor to Stanford University’s project. Edward Thorp, a donor to the University of California, Irvine project states: "Vivian and I believe that private donations like ours in support of stem cell research at UCI will have a benefit both to our community and to our country that is immeasurably greater than the amount of the gift. Stem cell research promises to transform the treatment of disease and to give us longer, healthier lives. We expect donor support will allow continuing breakthroughs by UCI's stellar research team and that this will be leveraged by attracting many times as much in continuing state support." Ray Dolby, a donor to the University of California San Francisco project stated: “Dagmar and I are very happy to see the ongoing progress of CIRM activities and wish the project continued success." Li Ka-shing, a Hong Kong philanthropist and entrepreneur and donor to the University of California, Berkeley project stated: “When I made a gift to support the establishment of the Li Ka Shing Center for Biomedical and Health Sciences at Berkeley, I was inspired by the passage of Prop. 71 and the promise of significant advances in stem cell research. I am pleased to partner with UC Berkeley and with CIRM to support focused efforts targeting the root causes of some of today's most devastating diseases and translate discoveries into new therapies.”


(Press the picture for larger version)

The table above details the amount of funding (in US$) each applicant will receive from CIRM, the donor and institutional funds, the total building cost, the additional funds committed for faculty recruitment and other project costs, and total project costs.
Major Facilities Grants The objectives of the CIRM Major Facilities Grant Program are:
  • Funding new facilities – and encouraging investments by others in new facilities – that are free of any federal funding so as to allow research and development of therapies based on human embryonic stem cell (hESC) and other stem cell approaches to proceed in California without restrictions imposed by the federal government.
  • Developing stem cell research centers that will expand research capacity and capabilities in California while bringing stem cell-related researchers together in a collaborative setting.
  • Funding new facilities and improvements where research institutions have determined that existing facilities are inadequate or are lacking altogether and thus pose a challenge to the development of therapies and cures for diseases being addressed at these institutions.

The applications seek funding to establish one of three types of CIRM facilities:

  • CIRM Institutes to carry out stem cell research in three categories: basic and discovery stem cell research, preclinical (translational) research, and preclinical development and clinical research. CIRM funding for these projects will be up to $50 million.
  • CIRM Centers of Excellence to conduct stem cell research in any two of the three categories listed above. CIRM funding for these project will be up to $25 million.
  • CIRM Special Program to conduct specialized stem cell projects in one of the categories listed above. CIRM funding for these project will be up to $10 million.

CIRM Grants Awarded Since the Start: Since April 2006 when the CIRM awarded its first scientific grants under the California Stem Cell Research and Cures Initiative, the Institute has funded 168 grants totalling more than $530 million for investigator-initiated research grants and training to 22 California non-profit and academic institutions.

  • The first grants directed $37.5 million for training 169 pre-doctoral, post-doctoral, and clinical fellows at 16 non-profit and academic research institutions.
  • In 2007 the ICOC approved 73 Leon J. Thal SEED Grants totalling more than $46 million to bring new ideas and new investigators into the field of human embryonic stem cell (hESC) research;
  • 28 Comprehensive Research Grants totalling nearly $72 million to support mature, ongoing studies on hESCs by scientists with a record of accomplishment in the field;
  • 17 Shared Research Laboratory Grants totalling more than $50 million;
  • 22 New Faculty Awards of more than $54 million to encourage the next generation of clinical and scientific leaders in stem cell research;
  • and today’s Major Facilities grants to 12 institutions totalling $271 million.

About CIRM: CIRM was established in 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The state-wide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. To date, the CIRM governing board has approved 168 research and facility grants totalling more than $530 million, making CIRM the largest source of funding for human embryonic stem cell research in the world. .........

ZenMaster
For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Wednesday, 7 May 2008

Stem Cell Policy Change Likely After Bush

Stem Cell Policy Change Likely After Bush Wednesday, 07 May 2008 Seven years after President Bush blocked most federal funding of embryonic stem cell research, the controversial science is likely to get a fresh look from the next President, no matter who it is. All three candidates left, Senators Hillary Rodham Clinton, Barack Obama and John McCain, have voted in favour of the Stem Cell Research Enhancement Act, which would have provided federal funding for stem cell research, including research using embryonic stem cells left over from fertility treatments. The bill was passed twice by the US congress in 2006 and 2007, but was vetoed both times by President Bush. Senators Barack Obama and Hillary Rodham Clinton both would overturn Bush's restrictions on the research quickly. Senator Hillary Clinton has several times during her campaign said she will immediately overturn President Bush’s executive order restricting the embryonic stem cell research. It is still slightly more uncertain how fast Senator Barack Obama will act, if he becomes president in January next year. Senator John McCain will, however, be under great pressure from pro-life and conservative groups to change his position on this issue, even though the Arizona Senator twice voted for legislation that would have lifted the limits Bush imposed. The Stem Cell Research Enhancement Act, based originally on a bill from Rep. Diana DeGette, Democrat from Colorado, would have allowed federal dollars to flow toward research on stem cell lines using embryos left over from in vitro fertilization, intended for disposal and donated by the parents. "I knew it was only a matter of time," DeGette said of the likely change to The Denver Post. "But I don't think anymore in this climate it's just enough to reverse the stem cell executive order." DeGette on Thursday will chair a House subcommittee hearing on stem cell research advances. DeGette plans to introduce a new stem cell bill, partly because of those advances and partly to lay the groundwork for the new president. She will propose the new legislation will direct federal researchers to launch a "Manhattan Project"-type effort on all stem cell research. The Denver Democrat also wants the National Institutes of Health to create an ethics panel on stem cell science. DeGette plans to introduce the bill later this year only to assess the support for it, not to press for its passage. "After two vetoes, President Bush will not sign my bill," she said to The Denver Post. So far, Senator Hillary Clinton has been the candidate who has expressed the strongest and longest support for embryonic stem cell research. The Candidates Views on Embryonic Stem Cell Research: Hillary Rodham Clinton: "It's time to unlock the potential of stem cell research and put an end to the backwards and restrictive policies of this administration," Clinton said. "Our scientists have been set back years in the race for life-saving cures because they've been held back by a narrow ideology that rejects sound science. As President, I will lift the ban on ethical embryonic stem cell research and allow our scientists to pursue treatments that could help millions of Americans." Clinton Pledges to Lift Ban on Stem Cell Research as President 6/15/2007 Barack Obama: Fact Sheet on Investing in Science: Advance Stem Cell Research: Despite recent advances pointing to alternatives like adult stem cell and cord blood, embryonic stem cells remain unmatched in their potential for treatment of a wide variety of diseases and health conditions. Barack Obama has been a long-term supporter of increased stem cell research. He introduced legislation while a member of the Illinois Senate that would allow embryonic stem cell research in Illinois. Obama has cosponsored legislation to allow greater federal government funding on a wider array of stem cell lines. Obama believes we need high ethical standards that allow for research on stem cells derived from embryos produced for in vitro fertilization, embryos that would otherwise be needlessly destroyed. John McCain: McCain has reaffirmed his support for embryonic stem cell research, which he said has split abortion foes. "It's very tough for those of us in the pro-life community," McCain told reporters. "I've prayed a lot about it, but I've come down on the side of support for embryonic stem cell research. It has split the pro-life community." September 17, 2007 statement to reporters (Published in The Boston Globe). Legislation: All three candidates voted in favour of the Stem Cell Research Enhancement Act, which would have provided federal funding for stem cell research, including research using embryonic stem cells left over from fertility treatments. The bill was passed twice by the US congress in 2006 and 2007, but was vetoed both times by President Bush. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Tuesday, 6 May 2008

Embryonic Stem Cell Therapies for Liver, Bone and Cartilage

University of Edinburgh Human Embryonic Stem Cell Program Awarded UK Grant Funding Grant Supports University Collaboration With Geron Corporation Tuesday, 06 May 2008 Geron Corporation announced today two grant awards to the University of Edinburgh from the UK Stem Cell Foundation, with funding from the Medical Research Council and Scottish Enterprise. The awards, totalling £3.6 million (US$7.2 million) over two years, follow on from a collaboration set up in August 2006 between Geron and the University of Edinburgh to develop hESC-derived hepatocytes for the treatment of liver failure and for use in cell-based assays, as well as to develop osteoblasts and chondrocytes for the treatment of musculoskeletal disorders such as osteoporosis, bone fractures and osteoarthritis. The grants relate to preclinical safety and efficacy studies of three therapeutic cell types derived from human embryonic stem cells (hESCs). The projects are led by Dr. Brendon Noble and Prof. John Iredale at the University of Edinburgh’s MRC Centre for Regenerative Medicine. “These are the first grants we have awarded that use human embryonic stem cells,” said Sir Richard Sykes, Chairman of the Board of Trustees, UK Stem Cell Foundation. “Our remit is to support high quality translational projects whose direct aim is rapid and safe progression towards clinical application. These research groups combine scientific and clinical expertise within a centre of excellence for stem cell research at the University of Edinburgh and are therefore well positioned for achieving success.” “The UK continues to demonstrate international leadership in supporting development of embryonic stem cell technology,” said David Greenwood, Geron’s executive vice president and chief financial officer. “Because of the receptiveness in the UK, we have major collaborations in place at the University of Edinburgh, the University of Birmingham and Oxford.” “This funding and our continued collaboration with Geron will advance two important translational programs within the MRC Centre for Regenerative Medicine,” commented Professor Sir John Savill, Head of College of Medicine and Veterinary Medicine at the University of Edinburgh. “The government has made a major investment in creating the Centre and this grant will allow us to progress toward our goal of delivering new treatments for debilitating diseases.” Programs Funded by the Grant Hepatocytes Currently, the only treatment for chronic end-stage liver failure is whole organ liver transplantation, a costly procedure limited by the severe shortage of donor organs. A potential alternative therapy being explored within the collaboration is the use of hepatocytes derived from hESCs either to restore liver function, or to be incorporated into bioartificial devices for patients awaiting transplantation or in need of short-term hepatic support. In the liver program, recent improvements in the hepatocyte differentiation protocol have significantly increased the efficiency of producing functional human hepatocyte-like cells. These derived cells have important genetic and functional characteristics of normal human hepatocytes, such as the expression of genes required for liver cell function and the ability of the cells to metabolize drugs. The current funding will support preclinical studies to assess safety and efficacy of the hESC-derived hepatocyte-like cells. An immediate goal of the work will be the development of the cells for drug testing. Successful development of liver cells from hESCs will revolutionise and improve the way we are able to test drugs and novel therapies both for the liver and other organs in addition to the possible development of a stem-cell based approach to regenerate the liver. Bone and Cartilage Cells Similarly, orthopaedic indications are important targets for cell therapy, such as the replacement of degenerated cartilage in osteoarthritis, or of bone after trauma or osteoporosis, applications with major unmet needs. These hESC-based therapies are intended to be off-the-shelf products, delivered on demand, and centrally produced from a uniform renewable source of undifferentiated cells, allowing efficient treatment of large numbers of patients. The orthopaedic program has derived bone forming osteoblasts and cartilage-forming chondrocytes from hESCs in vitro by directed differentiation and demonstrated survival of grafted cells in bone and cartilage repair sites in vivo. Cells derived in this way have been shown to be capable of forming the authentic bone and cartilage material that is required to repair our skeleton and to be capable of doing this in sites in the body that need it. The current funding will support further studies to assess safety and efficacy of hESC-derived osteoblasts and chondrocytes in preclinical models. Bioactive scaffolds and cell carriers, developed at the University of Edinburgh, will be used to promote tissue regeneration in vivo. About the Participants of the Program: The University of Edinburgh’s MRC Centre for Regenerative Medicine (CRM) is based at Little France medical campus, combining the Royal Infirmary of Edinburgh, an 870-bed teaching hospital, with the University of Edinburgh’s world-renowned Medical School and Queen’s Medical Research Institute adjacent to a 100-acre science park development, Edinburgh BioQuarter. The CRM was launched in December 2005 to advance basic research in stem cells and regenerative medicine with the goal of translating science and technology into clinical application. Under the directorship of Professor Sir Ian Wilmut FRS, who led the team that cloned Dolly the sheep, the CRM is already one of the largest critical masses of basic and clinical researchers in this field in Europe. It recently received full status as an MRC Centre of Excellence in regenerative medicine and stem cell research as part of the UK’s strategic investment in the field. The UK Stem Cell Foundation is a registered charity established in 2005 to support the advance of pioneering stem cell research into clinical practice and bridge the gap in the funding available for translational projects. A strategic funding partnership has been set up with the UK’s Medical Research Council (MRC) as part of a wider initiative to strengthen the Government’s commitment to stem cell research and boost investment in its translation in order to maintain a leading position in the field internationally. Scottish Enterprise (SE) is Scotland’s main enterprise, innovation and investment agency and is focused on supporting business growth and developing a competitive business environment. Working in partnership with industry, academia and the public sector, SE aims to play its part in delivering the Scottish Government’s new economic strategy to increase productivity in Scotland by helping businesses grow, encouraging greater innovation and creating the right conditions for companies to access property, markets and finance. Geron is a Menlo Park, California-based biopharmaceutical company developing first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html